Last reviewed · How we verify
PF-07081532 (pf-07081532)
PF-07081532 is a novel therapeutic agent currently under investigation by Pfizer. Without complete FDA mechanism text or approved indication information provided, a full clinical summary cannot be accurately generated. Please provide the complete mechanism of action and approved indication for accurate characterization.
At a glance
| Generic name | pf-07081532 |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | Experimental oral GLP-1 drug |
| Modality | Peptide |
| Therapeutic area | Metabolic |
| Phase | discontinued |
Approved indications
Pipeline indications
- Obesity — discontinued
Common side effects
Key clinical trials
- A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range (PHASE1)
- A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult Participants (PHASE1)
- A Clinical Trial of the Study Medicine (PF-07081532) in People With Diabetes and Kidney Dysfunction (PHASE1)
- A Study to Understand How the Study Medicine (PF-07081532) is Processed and Eliminated in Healthy Men (PHASE1)
- A Drug-Drug Interaction Study to Examine the Impact of Itraconazole and Cyclosporine on PF-07081532 Pharmacokinetics in Overweight or Obese Adults (PHASE1)
- A Study to Understand How the Study Medicine (PF-07081532) is Processed in People With Liver Dysfunction (PHASE1)
- Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus (PHASE1)
- A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF-07081532 CI brief — competitive landscape report
- PF-07081532 updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI